{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:34:26Z","timestamp":1793885666669,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtct.2026.06.038","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:15:54Z","timestamp":1782803754000},"page":"1455.e1-1455.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reduced-Dose Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Stem Cell Transplantation: A Systematic Review of Efficacy and Toxicity"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1202-7214","authenticated-orcid":false,"given":"Areez","family":"Shafqat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4889-8087","authenticated-orcid":false,"given":"Malaz","family":"El-Sibai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Nasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Kotb","family":"Abdrabou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alahmari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed O.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Hanbali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Rasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazza","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-7927","authenticated-orcid":false,"given":"Shahrukh K.","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0003-0130","authenticated-orcid":false,"given":"Ayman","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad El","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa F. Mohammed","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9674","key":"10.1016\/j.jtct.2026.06.038_bib0001","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.038_bib0002","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.038_bib0003","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa2503189","article-title":"Graft-versus-Host disease prophylaxis with cyclophosphamide and cyclosporin","volume":"393","author":"Curtis","year":"2025","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.jtct.2026.06.038_bib0004","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jtct.2026.06.038_bib0005","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.038_bib0006","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood.2025030416","article-title":"Posttransplant cyclophosphamide in HLA-matched peripheral blood transplantation: what\u2019s next?","volume":"147","author":"Curtis","year":"2026","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.038_bib0007","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.18483","volume":"200","author":"Zhang","year":"2023","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.038_bib0008","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jtct.2025.11.034","article-title":"Low-dose post-transplant cyclophosphamide in haploidentical stem cell transplantation: a systematic review","volume":"32","author":"Shafqat","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.06.038_bib0009","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jtct.2026.06.038_bib0010","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2019"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.038_bib0011","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.11124\/JBIES-23-00139","article-title":"Guidance to best tools and practices for systematic reviews","volume":"21","author":"Kolaski","year":"2023","journal-title":"JBI Evidence Synthesis"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.038_bib0012","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"10","key":"10.1016\/j.jtct.2026.06.038_bib0013","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/s41409-022-01754-y","volume":"57","author":"Zu","year":"2022","journal-title":"Bone Marrow Transplantation"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.038_bib0014","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-022-00771-w","article-title":"Low-dose PTCy plus low-dose ATG as GVHD prophylaxis after UD-PBSCT for hematologic malignancies: a prospective, multicenter, randomized controlled trial","volume":"13","author":"Zu","year":"2023","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.038_bib0015","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41409-018-0111-y","article-title":"Allogenic peripheral stem cell transplantation from HLA-matched related donors for adult sickle cell disease: remarkable outcomes from a single-center trial","volume":"53","author":"Ozdogu","year":"2018","journal-title":"Bone Marrow Transplantation"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.038_bib0016","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1038\/s41409-020-0805-9","article-title":"Excellent outcomes of allogeneic transplantation from peripheral blood of HLA-matched related donors for adult sickle cell disease with ATLG and posttransplant cyclophosphamide-containing regimen: an update work","volume":"55","author":"Ozdogu","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.038_bib0017","doi-asserted-by":"crossref","first-page":"213.e1","DOI":"10.1016\/j.jtct.2022.01.011","article-title":"Risk of Cytomegalovirus infection with post-transplantation cyclophosphamide in haploidentical and HLA-matched unrelated donor transplantation","volume":"28","author":"Jamy","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.038_bib0018","doi-asserted-by":"crossref","first-page":"298.e1","DOI":"10.1016\/j.jtct.2025.10.020","article-title":"Modifying post-transplant cyclophosphamide platform to improve safety in HLA-matched allogeneic HCT: a reduced dose plus adjunctive strategies","volume":"32","author":"Pinto","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.038_bib0019","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/ejh.70010","article-title":"Standard versus reduced-doses of post-transplant cyclophosphamide in HLA matched (10\/10) peripheral blood stem cell transplantation","volume":"115","author":"Redondo","year":"2025","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.038_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2024.104058","article-title":"What should be the optimal dose of post-transplantation cyclophosphamide for GVHD prophylaxis in allogeneic stem cell transplantation?","volume":"64","author":"Ulas","year":"2025","journal-title":"Transfusion Apheresis Sci"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.038_bib0021","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41409-025-02581-7","article-title":"Feasibility and efficacy of partial replacement of post transplantation cyclophosphamide with bendamustine on day +4 for graft versus host disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation","volume":"60","author":"Nair","year":"2025","journal-title":"Bone Marrow Transplantation"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.038_bib0022","doi-asserted-by":"crossref","first-page":"253p","DOI":"10.1038\/s41598-020-80531-7","article-title":"Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA","volume":"11","author":"Zu","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.038_bib0023","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/bjh.70380","article-title":"Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia","volume":"208","author":"Desai","year":"2026","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.038_bib0024","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41409-025-02564-8","article-title":"Anti-T lymphocyte globulin plus posttransplant cyclophosphamide 25 mg\/kg versus posttransplant cyclophosphamide 50 mg\/kg in patients with acute leukemias","volume":"60","author":"Karakus","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.038_bib0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41598-020-80531-7","article-title":"Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA","volume":"11","author":"Zu","year":"2021","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.038_bib0026","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.038_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/bloodadvances.2025016589","article-title":"BK virus kinetics and associated cystitis\/urethritis symptoms after PTCy-based allogeneic hematopoietic cell transplant","volume":"10","author":"Dimitrova","year":"2025","journal-title":"Blood Adv"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:21:16Z","timestamp":1793884876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726005129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2666636726005129"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.038","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced-Dose Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Stem Cell Transplantation: A Systematic Review of Efficacy and Toxicity","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}